Article
SARS-CoV-2 infection enhancement by Amphotericin B: Implications for disease management
medRxiv · 2025 · Nguyen, D.; Laidlaw, S. M.; Dong, X.; Wand, M. E.; Horton, A.; Sutton, M.; Tree, J.; Milligan, R.; Erdmann, M.; Matthews, D. A.; Davidson, A. D.; Rahman, K. M.; Hiscox, J. A.; Carroll, M. W.
Key facts
| Title | SARS-CoV-2 infection enhancement by Amphotericin B: Implications for disease management |
|---|---|
| First author | Nguyen, D.; Laidlaw, S. M.; Dong, X.; Wand, M. E.; Horton, A.; Sutton, M.; Tree, J.; Milligan, R.; Erdmann, M.; Matthews, D. A.; Davidson, A. D.; Rahman, K. M.; Hiscox, J. A.; Carroll, M. W. |
| Journal | medRxiv |
| Published | Jan 1, 2025 |
| DOI | 10.1101/2024.11.07.622419 |
| Product codes mentioned | KIP, KIT, NDS, PFF, PFT |
At a glance
- None FDA submissions mentioned
- 1–9 Product codes mentioned
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Literature
Peer-reviewed and preprint literature indexed by Orca1 and linked to the FDA submissions and product codes each article mentions. Only bibliographic details are shown here.
Source: Publisher and PubMed metadata; device mentions identified by Orca1